# Helen Bronte-Stewart **Entity class:** Person **Domain:** Movement Disorders / Adaptive Neuromodulation **Doc Type:** Person Node **Maturity:** Developed **Collection:** [[collections/Neurotech|Neurotech]] **Primary Sources:** [[research/Research Inferences|Research Inferences]] (INF-0069) ## Definition **Helen Bronte-Stewart is a neurologist at [[wiki/Stanford University|Stanford]], holder of the John E. Cahill Family Professorship in the Department of Neurology and Neurological Sciences, and global lead investigator of ADAPT-PD, the first pivotal international multicenter trial of adaptive deep brain stimulation in Parkinson's disease.** Her laboratory developed Quantitative DigitoGraphy, a keyboard-based measure of movement abnormality, and the first metric of freezing of gait. Sources differ on her current administrative titles; the Michael J. Fox Foundation lists her as director of the Stanford Comprehensive Movement Disorders Center, co-director of the Stanford Balance Center and division chief of movement disorders. ## Work in the corpus ADAPT-PD is the trial behind [[wiki/BrainSense Adaptive DBS|BrainSense Adaptive DBS]], which the FDA approved on 24 February 2025. It compared chronic single- and dual-threshold adaptive stimulation against continuous stimulation in a randomized crossover design, in clinic and in patients' homes. That home component is what makes the dataset consequential for the corpus: continuous neural telemetry outside the clinic is the precondition for any longitudinal model of a person's neural state. ## Reading Her career is the register's clearest instance of a transfer mechanism that runs through people rather than patents. The academic neuromodulation laboratories that validated adaptive stimulation are the same ones supplying the clinical leadership of the implant industry, and the transfer is documented in trial authorship. The therapy she validated now runs on more than 40,000 [[wiki/Medtronic|Medtronic]] Percept devices, the largest installed base of sensing brain implants in the world. ## Research Inferences These entries translate the forward-looking register in [[research/Research Inferences|Research Inferences]] into ordinary wiki prose. The tier labels apply to the inference, not automatically to every factual anchor inside it. Proposed IDs above INF-0500 come from the 2026-10-23 cycle: [[research/Research Inferences Integration Report - 2026-10-23|Research Inferences Integration Report — 2026-10-23]] · [[research/Research Inferences Integration Audit - 2026-10-23|Research Inferences Integration Audit — 2026-10-23]]. - **INF-0069 — Established.** The academic neuromodulation laboratories that validated adaptive stimulation are the same ones supplying the clinical leadership of the implant industry. The people are the transfer mechanism, and the transfer is documented in trial authorship. - **INF-0062 — Established.** BrainSense reads local field potentials and adjusts stimulation in real time, which is a closed control loop running continuously inside a human brain, approved and reimbursed. The architecture the continuity literature describes as speculative is in commercial distribution under a movement-disorder indication. - **INF-0063 — Strongly indicated.** ADAPT-PD evaluated adaptive stimulation in clinical *and home* settings across 68 patients over a year, which means the dataset includes unsupervised daily life. Continuous neural telemetry outside the clinic is the precondition for every longitudinal model of a person's neural state. - **INF-0061 — Established.** More than 40,000 patients carry Medtronic Percept devices, making adaptive DBS the largest commercial deployment of brain-computer interface technology that has ever existed. The installed base of sensing neural implants is already measured in tens of thousands, and it is clinical rather than experimental. - **INF-0459 — Analytic.** Appointing an academic leader into a company transfers a laboratory's methods, students, and collaborations along with the individual. Senior appointments are therefore the highest-bandwidth technology-transfer events available and should be read as such. ## Relationships - **institution:** [[wiki/Stanford University|Stanford University]]; John E. Cahill Family Professor, Neurology and Neurological Sciences. - **principal_investigator_of:** ADAPT-PD, the trial behind [[wiki/BrainSense Adaptive DBS|BrainSense Adaptive DBS]]. - **manufacturer_context:** [[wiki/Medtronic|Medtronic]]. - **indication:** [[wiki/Parkinson's Disease|Parkinson's Disease]]. - **capability_class:** [[wiki/Closed-Loop Neuromodulation|Closed-Loop Neuromodulation]] · [[wiki/Closed-Loop Control|Closed-Loop Control]]. - **cluster_home:** [[wiki/Distributed Biological Interfaces|Distributed Biological Interfaces]]. - **ecosystem:** [[wiki/Neurotechnology Ecosystem|Neurotechnology Ecosystem]] · [[collections/Neurotech|Neurotech]]. ## Sources - [Helen Bronte-Stewart — Stanford Profiles](https://profiles.stanford.edu/helen-bronte-stewart) - [Helen Bronte-Stewart, MD, MSE — Michael J. Fox Foundation](https://www.michaeljfox.org/researcher/helen-bronte-stewart-md-mse) - [Deep adaptive brain stimulation for Parkinson's — Stanford Medicine, February 2025](https://med.stanford.edu/news/all-news/2025/02/deep-adaptive-brain-stimulation-parkinsons.html) - [Chronic adaptive deep brain stimulation in Parkinson's disease: ADAPT-START findings — npj Parkinson's Disease, 2026](https://www.nature.com/articles/s41531-026-01269-z) As of 23 October 2026.